Chicago Growth Partners

Chicago Growth Partners, LLC, established in 2004, is a Chicago-based private equity firm focusing on mid-market investments. The company specializes in providing expansion and buyout capital to growth-oriented businesses, typically investing between $5 million and $75 million. It targets companies with revenues ranging from $10 million to $200 million and EBITDA between $3 million and $30 million, seeking a minimum growth rate of 15% and profit margins exceeding 20%. Chicago Growth Partners invests across various sectors, including business and consumer services, healthcare, technology, and industrial growth sectors, with a particular interest in niche, disruptive technologies. The firm takes a flexible approach to investment structures, considering both control and non-control positions, and aims to hold investments for three to seven years.

Arda Minocherhomjee Ph.D

Managing Partner

16 past transactions

EndoGastric Solutions

Series I in 2018
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions

Venture Round in 2015
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

2Checkout

Series A in 2014
2Checkout is a prominent all-in-one monetization platform that enables businesses of all sizes to enhance their global sales operations. The company provides digital commerce and payments software designed to streamline various aspects of modern commerce, including global payments, subscription billing, and tax compliance. By simplifying these complexities, 2Checkout allows clients to focus on product innovation and improving customer experiences. Its solutions support multiple sales channels and touchpoints, helping businesses acquire and retain customers more effectively while maximizing sales conversion rates. Ultimately, 2Checkout aims to facilitate easier and more efficient global online sales, empowering clients to drive revenue growth and expand their market presence.

Medical Scribe Systems

Debt Financing in 2014
ScribeAmerica was established in 2003, while the concept of medical scribe utilization in the industry has been anecdotally reported since the 1970's, ScribeAmerica transformed this cottage operation into a national industry. In 2006, we were the first company to demonstrate that the synergy of the Scribe/MD/EMR model could overcome productivity losses experienced by unassisted physicians using EMR. In 2008, we were the first scribe company providing services on both coasts and the only scribe company present at ACEP, AAOS, and SHM. We credit our success to our generous profit-sharing business model whereby the actual Project Leaders who manage our client's programs are rewarded. By enfranchising our employee base, we ensure limited attrition among management and attract the best talent in the industry to run your program.

EndoGastric Solutions

Series G in 2014
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions

Venture Round in 2012
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions

Venture Round in 2012
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions

Series F in 2010
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Zogenix

Venture Round in 2010
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

EndoGastric Solutions

Series E in 2010
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Zogenix

Series B in 2009
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

EndoGastric Solutions

Venture Round in 2009
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions

Venture Round in 2009
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Xoft

Series E in 2008
Xoft, Inc. specializes in the development of electronic brachytherapy (eBx) systems designed for radiation oncology applications. The company’s flagship product, the Axxent Controller, employs a miniaturized high dose rate X-ray source to deliver targeted radiation directly to cancerous tumor beds. Xoft also provides a range of applicators, including the Axxent balloon applicator for accelerated partial breast irradiation, the Axxent vaginal applicator for vaginal brachytherapy, and the Axxent surface applicator for treating surface lesions. Additionally, the company offers a variety of accessories to support its products, such as physics accessory kits and protective shields to minimize radiation exposure to healthy tissues. Xoft’s innovative solutions are primarily utilized in the treatment of early-stage breast cancer, skin cancer, and endometrial cancer, and the products are distributed through physicians and distributors across Europe. Founded in 1998 and based in Sunnyvale, California, Xoft was previously known as Xoft microTube, Inc. before rebranding in 2004.

TargeGen

Series D in 2007
TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2002. The company specializes in the discovery and development of small molecule kinase inhibitors aimed at addressing vascular leakage, vascular proliferation, and inflammation. TargeGen's products are designed for the treatment of various serious medical conditions, including heart attacks, cancer, and eye diseases. Specifically, their therapies target issues like vascular leakage, edema, unwanted growth of new blood vessels, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and central nervous system disorders. The company has a particular focus on markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. In 2010, TargeGen was acquired by Sanofi Aventis.

Compete

Series B in 2003
Compete, Inc. specializes in digital intelligence services aimed at enhancing marketing strategies for brands by analyzing consumer online behavior. The company provides valuable insights into consumer behavior, enabling businesses to research competitors, benchmark performance, and identify effective keywords and referral sources. Compete offers tools to track online market shares among competitors and product categories, analyze traffic sources, and improve website engagement and conversion metrics. Additionally, it helps identify cross-selling and up-selling opportunities, measure referral partnerships, and reduce customer care costs, all while fostering customer loyalty through actionable intelligence. The company also focuses on mobile behavioral intelligence to understand the impact of mobile devices on consumer shopping experiences, further enriching its data-driven insights for brands.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.